PDCD4 and neoplasm: Additionally, other blood markers such as T-cell factor 4 (TCF4), programmed cell death 4 (PDCD4), and circulating lymphocytes have all shown predictive potential for favorable tumor response and prognosis in patients with LARC undergoing nCRT (108–110).